Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study. Issue 6 (2nd June 2020)

• Record Type: Journal Article
• Authors: Piekarska, A.; Jabłonowska, E.; Garlicki, A.; Sitko, M.; Mazur, W.; Jaroszewicz, J.; Czauz-Andrzejuk, A.; Buczyńska, I.; Simon, K.; Lorenc, B.; Dybowska, D.; Halota, W.; Pawłowska, M.; Dobracka, B.; Berak, H.; Horban, A.; Tudrujek-Zdunek, M.; Tomasiewicz, K.; Janczewska, E.; Socha, Ł.; Laurans, Ł.; Parczewski, M.; Zarębska-Michaluk, D.; Pabjan, P.; Belica-Wdowik, T.; Baka-Ćwierz, B.; Deroń, Z.; Krygier, R.; Klapaczyński, J.; Citko, J.; Berkan-Kawińska, A.; Flisiak, R.;
• Is Part Of: AIDS care. Volume 32:Issue 6(2020)
• Page Start: 762
• Page End: 769
• Publication Date: 2020-06-02
• Subjects: Hepatitis C -- HCV/HIV coinfection -- DAA treatment; AIDS (Disease) -- Social aspects -- Periodicals; AIDS (Disease) -- Psychological aspects -- Periodicals; AIDS (Disease) -- Patients -- Care -- Periodicals; Acquired Immunodeficiency Syndrome; 362.1969792
• DOI: 10.1080/09540121.2019.1645808
• Languages: English
• ISSNs: 0954-0121

Abstract

ABSTRACT: The aim of this study was to evaluate the baseline demographics and real-life efficacy of direct acting antivirals (DAAs) in HIV–HCV-positive patients as compared to patients with HCV monoinfection. The analysis included 5690 subjects who were treated with DAAs: 5533 were HCV-positive and 157 were HIV–HCV-positive. Patients with HCV-monoinfection were older ( p < .0001) and in HIV–HCV group there were more men ( p < .0001). Prevalence of genotype 1a ( p = .002), as well as of genotypes 3 and 4 ( p < .0001) was higher in HIV–HCV-coinfected patients. Genotype 1b was more frequent ( p < .0001) in the HCV-mono-infection group. Patients with HCV-monoinfection had a higher proportion of fibrosis F4 ( p = .0004) and lower proportion of fibrosis F2 ( p < .0001). HIV–HCV-coinfected individuals were more often treatment-naïve ( p < .0001). Rates of sustained viral response after 12 weeks did not differ significantly between both groups (95.9% versus 97.3% in coinfection and monoinfection group, respectively; p > .05). They were, however, influenced by HCV genotype ( p < .0001), stage of hepatic fibrosis ( p < .0001), male sex ( p < .0001), BMI ( p = .0001) and treatment regimen modifications ( p < .0001). Although factors associated with worse response to therapy (male sex, genotype 3) occurred more often in the HIV coinfection group, real-life results of DAAs did not differ significantly between both populations.